HOMEPRODUCTSCOMPANYCONTACTFAQResearchDictionaryPharmaSign Up FREE or Login

Review of rifaximin as treatment for SIBO and IBS.

AbstractBACKGROUND:
Rifaximin is a broad-range, gastrointestinal-specific antibiotic that demonstrates no clinically relevant bacterial resistance. Therefore, rifaximin may be useful in the treatment of gastrointestinal disorders associated with altered bacterial flora, including irritable bowel syndrome (IBS) and small intestinal bacterial overgrowth (SIBO).
OBJECTIVE:
To review rifaximin for treatment of IBS and SIBO.
METHODS:
Review of rifaximin clinical trials.
RESULTS/CONCLUSION:
Rifaximin improved global symptoms in 33 - 92% of patients and eradicated SIBO in up to 84% of patients with IBS, with results sustained up to 10 weeks post-treatment. Rifaximin caused a lower number of adverse events compared with metronidazole or levofloxacin and may have a more favorable adverse event profile than systemic antibiotics, without clinically relevant antibiotic resistance.
AuthorsMark Pimentel
JournalExpert opinion on investigational drugs (Expert Opin Investig Drugs) Vol. 18 Issue 3 Pg. 349-58 (Mar 2009) ISSN: 1744-7658 [Electronic] England
PMID19243285 (Publication Type: Journal Article, Review)
Chemical References
  • Rifamycins
  • Rifaximin
Topics
  • Animals
  • Clinical Trials as Topic
  • Drug Tolerance
  • Humans
  • Intestinal Diseases (diagnosis, drug therapy, microbiology)
  • Microbial Viability (drug effects)
  • Rifamycins (chemistry, metabolism, pharmacology, therapeutic use)
  • Rifaximin

Join CureHunter, for free Research Interface BASIC access!

Take advantage of free CureHunter research engine access to explore the best drug and treatment options for any disease. Find out why thousands of doctors, pharma researchers and patient activists around the world use CureHunter every day.
Realize the full power of the drug-disease research graph!


Choose Username:
Email:
Password:
Verify Password:
Enter Code Shown: